Pancreatic Cancer Clinical Trials

Showing 461-480 of 1,019 trials

Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient

NCT06090825

It is a real-world observational cross-sectional follow-up study on clinical palliative care for pancreatic cancer patients in China. It is evaluated by an online questionnaire sent to the doctors from the General Surgery Department in more than 100 public tertiary teaching hospitals and about 350 public primary care units in the Chinese mainland.

Pancreatic Cancer

Peking Union Medical College Hospital450 participantsStarted Sep 2023

Beijing, Beijing Municipality, China

TERMINATEDPhase 2

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

NCT03714555

This is an open-label Phase 2 Pilot study to evaluate Disulfiram + Copper Gluconate in patients metastatic pancreatic cancer whose CA-19-9 levels rise while receiving nab-paclitaxel (Abraxane) plus gemcitabine (Gemzar) or FOLFIRINOX or single-agent gemcitabine (Gemzar). Patient must have received a minimum of 8 weeks of treatment and have rising CA-19-9 levels in the absence of radiographic evidence of progression.

Metastatic Pancreatic Cancer

HonorHealth Research Institute1 participantsStarted Oct 2019

Scottsdale, Arizona, United States

Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

Related Searches

Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma

A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)

Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis

High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors

Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer

Improving Pancreatic Cancer Care by the Use of Computational Science and Technology

Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source

Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma

Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression